Predictors of autosomal dominant polycystic kidney disease progression

Journal of the American Society of Nephrology

Volumn 25, Issue 11, 2014, Pages 2399-2418

  Schrier, Robert W ^a   Brosnahan, Godela ^a   Cadnapaphornchai, Melissa A ^a   Chonchol, Michel ^a   Friend, Keith ^b   Gitomer, Berenice ^a   Rossetti, Sandro ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; COPEPTIN; POLYCYSTIN 1; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIC KIDNEY DISEASE 2 PROTEIN; POLYCYSTIN;

ACUTE KIDNEY FAILURE; ALLELE; ANEURYSM RUPTURE; BIRTH WEIGHT; CARDIOVASCULAR DISEASE; CYST RUPTURE; DISEASE COURSE; EARLY INTERVENTION; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; FLUID INTAKE; GENE MUTATION; GENETIC HETEROGENEITY; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; LIVER DISEASE; MACROALBUMINURIA; MICROALBUMINURIA; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEINURIA; SEX DIFFERENCE; SHORT SURVEY; SMOKING; SYSTEMATIC REVIEW; GENETICS; KIDNEY; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE;

DISEASE PROGRESSION; HUMANS; KIDNEY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PREDICTIVE VALUE OF TESTS; TRPP CATION CHANNELS;

EID: 84911448589     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013111184     Document Type: Short Survey

References (109)

1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007
2. Takiar V, Caplan MJ: Polycystic kidney disease: Pathogenesis and potential therapies. BiochimBiophysActa 1812: 1337-1343, 2011
3. th Ed., edited by Schrier R, Philadelphia, Lippincott Williams & Wilkins, 2001, pp 547-588
4. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr., Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006
5. Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, Charasse C, Whebe B, Renaudineau E, Jousset P, Guillodo M-P, Grall-Jezequel A, Saliou P, Férec C, Le Meur Y: Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24: 1006-1013, 2013
6. Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, Revert L, Estivill X: Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol 7: 2142-2151, 1996
7. Johnson AM, Gabow PA: Identification of patients with autosomal dominant polycystic kidney disease at highest risk for endstage renal disease. J Am Soc Nephrol 8: 1560-1567, 1997
8. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D; European PKD1-PKD2 Study Group: Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet 353: 103-107, 1999
9. Dicks E, Ravani P, Langman D, Davidson WS, Pei Y, Parfrey PS: Incident renal events and risk factors in autosomal dominant polycystic kidney disease: A population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 1: 710-717, 2006
10. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP: Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 17: 3013-3019, 2006
11. Fencl F, Janda J, Bláhová K, Hríbal Z, StekrováJ, Puchmajerová A, Seeman T: Genotype-phenotype correlation in children with autosomal dominant polycystic kidney disease. Pediatr Nephrol 24: 983-989, 2009
12. Rossetti S, Chauveau D, Kubly V, Slezak JM, Saggar-Malik AK, Pei Y, Ong ACM, Stewart F, Watson ML, Bergstralh EJ, Winearls CG, Torres VE, Harris PC: Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 361: 2196-2201, 2003
13. Hateboer N, Veldhuisen B, Peters D, Breuning MH, San-Millán JL, Bogdanova N, Coto E, van Dijk MA, Afzal AR, Jeffery S, Saggar-Malik AK, Torra R, Dimitrakov D, Martinez I, de Castro SS, Krawczak M, Ravine D: Location of mutations within the PKD2 gene influences clinical outcome. Kidney Int 57: 1444-1451, 2000
14. Magistroni R, He N, Wang K, Andrew R, Johnson A, Gabow P, Dicks E, Parfrey P, Torra R, San-Millán JL, Coto E, Van Dijk M, Breuning M, Peters D, Bogdanova N, Ligabue G, Albertazzi A, Hateboer N, Demetriou K, Pierides A, Deltas C, St George-Hyslop P, Ravine D, Pei Y: Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14: 1164-1174, 2003
15. Pei Y, Lan Z, Wang K, Garcia-Gonzalez M, He N, Dicks E, Parfrey P, Germino G, Watnick T: A missense mutation in PKD1 attenuates the severity of renal disease. Kidney Int 81: 412-417, 2012
16. Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Torres VE, Harris PC: Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75: 848-855, 2009
17. Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC: Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol 21: 1097-1102, 2010
18. Losekoot M, Ruivenkamp CA, Tholens AP, Grimbergen JE, Vijfhuizen L, Vermeer S, Dijkman HB, Cornelissen EA, Bongers EM, Peters DJ: Neonatal onset autosomal dominant polycystic kidney disease (ADPKD) in a patient homozygous for a PKD2 missense mutation due to uniparental disomy. J Med Genet 49: 37-40, 2012
19. Reiterová J, Štekrová J, Merta M, Kotlas J, Elišáková V, Lněnička P, Korabečná M, Kohoutová M, Tesař V: Autosomal dominant polycystic kidney disease in a family with mosaicism and hypomorphic allele. BMC Nephrol 14: 59, 2013
20. Fain PR, McFann KK, Taylor MR, Tison M, Johnson AM, Reed B, Schrier RW: Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 67: 1256-1267, 2005
21. Pérez-Oller L, Torra R, Badenas C, Milà M, Darnell A: Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis 34: 273-278, 1999
22. Persu A, El-Khattabi O, Messiaen T, Pirson Y, Chauveau D, Devuyst O: Influence of ACE (I/D) and G460W polymorphism of a-adducin in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18: 2032-2038, 2003
23. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, Mourad M, Horie S, Feron O, Balligand JL, Wattiez R, Pirson Y, Chauveau D, Lens XM, Devuyst O: Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 11: 229-241, 2002
24. Zeltner R, Hilgers KF, Schmieder RE, Porst M, Schulze BD, Hartner A: A promoter polymorphism of the alpha 8 integrin gene and the progression of autosomal-dominant polycystic kidney disease. Nephron Clin Pract 108: c169-c175, 2008
25. Dedoussis GVZ, Luo Y, Starremans P, Rossetti S, Ramos AJ, Cantiello HF, Katsareli E, Ziroyannis P, Lamnissou K, Harris PC, Zhou J: Co-inheritance of a PKD1 mutation and homozygous PKD2 variant: A potentialmodifier in autosomal dominant polycystic kidney disease. Eur J Clin Invest 38: 180-190, 2008
26. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41: 1311-1319, 1992
27. Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grünfeld JP, Jungers P: Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6: 1634-1642, 1995
28. Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M: Autosomal dominant polycystic kidney disease in blacks: Clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 4: 1670-1674, 1994
29. Geberth S, Stier E, Zeier M, Mayer G, Rambausek M, Ritz E: More adverse renal prognosis of autosomal dominant polycystic kidney disease in families with primary hypertension. J Am Soc Nephrol 6: 1643-1648, 1995
30. Schrier RW, Johnson AM, McFann K, Chapman AB: The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 64: 1792-1799, 2003
31. Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, Parfrey P, Pei Y: Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 20: 1833-1838, 2009
32. Helal I, Reed B, McFann K, Yan XD, Fick-Brosnahan GM, Cadnapaphornchai M, Schrier RW: Glomerular hyper filtration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 2439-2443, 2011
33. Shah SV, Baliga R, Rajapurkar M, Fonseca VA: Oxidants in chronic kidney disease. J Am Soc Nephrol 18: 16-28, 2007
34. Tracz MJ, Alam J, Nath KA: Physiology and pathophysiology of heme: Implications for kidney disease. J Am Soc Nephrol 18: 414-420, 2007
35. Gabow PA, Duley I, Johnson AM: Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis 20: 140-143, 1992
36. Idrizi A, Barbullushi M, Petrela E, Kodra S, Koroshi A, Thereska N: The influence of renal manifestations to the progression of autosomal dominant polycystic kidney disease. Hippokratia 13: 161-164, 2009
37. Chapman AB, Johnson AM, Gabow PA: Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 1178-1185, 1994
38. Ahmed ER, Tashkandi MA, Nahrir S, Maulana A: Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease. Saudi J Kidney Dis Transpl 17: 511-515, 2006
39. Hwang JH, Park HC, Jeong JC, Ha Baek S, Han MY, Bang K, Cho JY, Yu SH, Yang J, Oh KH, Hwang YH, Ahn C: Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol 14: 1, 2013
40. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP, Serra AL: Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75: 235-241, 2009
41. Seeman T, Sikut M, Konrad M, Vondrichová H, Janda J, Schärer K: Blood pressure and renal function in autosomal dominant polycystic kidney disease. Pediatr Nephrol 11: 592-596, 1997
42. Seeman T, Dusek J, Vondrichová H, Kyncl M, John U, Misselwitz J, Janda J: Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 8: 107-110, 2003
43. Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA: The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4: 1654-1660, 1994
44. Shamshirsaz AA, RezaBekheirnia M, Kamgar M, Johnson AM, McFann K, Cadnapaphornchai M, Nobakhthaghighi N, Schrier RW: Autosomal dominant polycystic kidney disease in infancy and childhood: Progression and outcome. Kidney Int 68: 2218-2224, 2005
45. Gabow PA, Chapman AB, Johnson AM, Tangel DJ, Duley IT, Kaehny WD, Manco-Johnson M, Schrier RW: Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177-1180,1990
46. Augustyniak-Bartosik H, Krajewska M, Weyde W, Mazanowska O, Rurek M, Klinger M: The phenotypic characteristics of adult polycystic kidney disease have greater impact on the course of progressive disease than the type of mutation of the polycystin 1 gene. Adv Clin Exp Med 17: 155-159, 2008
47. Gonzalo A, Gallego A, Rivera M, Orte L, Ortuño J: Influence of hypertension on early renal insufficiency in autosomal dominant polycystic kidney disease. Nephron 72: 225-230, 1996
48. Ozkok A, Akpinar TS, Tufan F, Kanitez NA, Uysal M, Guzel M, Caliskan Y, Alisir S, Yazici H, Ecder T: Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: A single center experience. Clin Exp Nephrol 17: 345-351, 2013
49. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 13: 1733-1739, 2002
50. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 35: 427-432, 2000
51. Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD: Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23: 573-579, 2008
52. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW; HALT PKD Study Group: Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 81: 577-585, 2012
53. Franco Palacios C, Keddis MT, Qin D, Zand L, Li G, Wang X, Cartin-Ceba R, Hartman RP, Qian Q: Acute kidney injury in ADPKD patients with pneumonia. Int J Nephrol 2011: 617904, 2011
54. Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA: Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 59: 1654-1662, 2001
55. Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW: Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study. Am J Kidney Dis 39: 1127-1134, 2002
56. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr., Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64: 1035-1045, 2003
57. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479-486, 2012
58. King BF, Torres VE, Brummer ME, Chapman AB, Bae KT, Glockner JF, Arya K, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP): Magnetic resonance measurements of renal blood flow as amarker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 64: 2214-2221, 2003
59. Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP):Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2: 112-120, 2007
60. Meijer E, Rook M, Tent H, Navis G, van der Jagt EJ, de Jong PE, Gansevoort RT: Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5: 1091-1098, 2010
61. Taylor M, Johnson AM, Tison M, Fain P, Schrier RW: Earlier diagnosis of autosomal dominant polycystic kidney disease: Importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis 46: 415-423, 2005
62. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW: Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8: 1292-1297, 1997
63. Valero FA, Martinez-Vea A, Bardají A, Gutierrez C, Garcia C, Richart C, Oliver JA: Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10: 1020-1026, 1999
64. Bardají A, Vea AM, Gutierrez C, Ridao C, Richart C, Oliver JA: Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 32: 970-975, 1998
65. Martinez-Vea A, Bardají A, Gutierrez C, Garca C, Peralta C, Marcas L, Oliver JA: Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: A prehypertensive state. Am J Kidney Dis 44: 216-223, 2004
66. Martinez-Vea A, Valero FA, Bardají A, Gutierrez C, Broch M, Garcia C, Richart C, Oliver JA: Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: Influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol 20: 193-200, 2000
67. Zeier M, Geberth S, Schmidt KG, Mandelbaum A, Ritz E: Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3: 1451-1457, 1993
68. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW: Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74: 1192-1196, 2008
69. Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Dobin A, Gabow PA: Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 2032-2036, 1995
70. Patch C, Charlton J, Roderick PJ, Gulliford MC: Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: A population-based study. Am J Kidney Dis 57: 856-862, 2011
71. Schrier RW, McFann KK, Johnson AM: Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 63: 678-685, 2003
72. Orskov B, Rømming Sørensen V, Feldt-Rasmussen B, Strandgaard S: Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 5: 2034-2039, 2010
73. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Bae KT: HALT PKD Study Group: Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 2508-2515, 2011
74. Belz MM, Hughes RL, Kaehny WD, Johnson AM, Fick-Brosnahan GM, Earnest MP, Gabow PA: Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am J Kidney Dis 38: 770-776, 2001
75. Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, Alisir S, Turgut F, Mercanoglu F, Ecder T: Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 43: 854-860, 2004
76. Ramunni A, Brescia P, Quaranta D, Bianco MS, Ranieri P, Dolce E, Coratelli P: Cutaneous microcirculation is impaired in early autosomal dominant polycystic kidney disease. Nephron Clin Pract 113: c71-c75, 2009
77. Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V: Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 26: 2515-2521, 2011
78. Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME; Modification of Diet in Renal Disease Study Group: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 5: 2037-2047, 1995
79. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 1349-1354, 1994
80. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112-119, 2006
81. Morgenthaler NG, Struck J, Jochberger S, Dünser MW: Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 19: 43-49, 2008
82. Meijer E, Bakker SJL, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 361-368, 2011
83. Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP: Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: Results from the CRISP cohort. Am J Kidney Dis 61: 420-429, 2013
84. Meijer E, Boertien WE, Nauta FL, Bakker SJL, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJM, Navis G, de Jong PE, Gansevoort RT: Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis. Am J Kidney Dis 56: 883-895, 2010
85. Reed BY, Masoumi A, Elhassan E, McFann K, Cadnapaphornchai MA, Maahs DM, Snell-Bergeon JK, Schrier RW: Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int 79: 128-134, 2011
86. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF Jr., Wetzel LH, Martin D, Lockhart ME, Bennett WM, Moxey-Mims M, Abebe KZ, Lin Y, Bost JE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP): Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 640-647, 2011
87. Helal I, McFann K, Reed B, Yan X-D, Schrier RW, Fick-Brosnahan GM: Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 28: 380-385, 2013
88. Kocyigit I, Yilmaz MI, Orscelik O, Sipahioglu MH, Unal A, Eroglu E, Kalay N, Tokgoz B, Axelsson J, Oymak O: Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Nephron Clin Pract 123: 157-164, 2013
89. Zheng D, Wolfe M, Cowley BD Jr., Wallace DP, Yamaguchi T, Grantham JJ: Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14: 2588-2595, 2003
90. Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M: Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 6: 7-13, 2011
91. Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C, Rentsch KM, Wüthrich RP, Serra AL: Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 79: 234-240, 2011
92. Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB: Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: A multicentric study. PLoS ONE 8: e53016, 2013
93. Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, Zeltner R, Tian X, Grantham JJ, Somlo S: Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int 81: 784-790, 2012
94. Ta MH, Harris DC, Rangan GK: Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology (Carlton) 18: 317-330, 2013
95. Orskov B, Christensen KB, Feldt-Rasmussen B, Strandgaard S: Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease. Kidney Int 81: 919-924, 2012
96. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ: The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 13: 2723-2729, 2002
97. Vendramini LC, Nishiura JL, Baxmann AC, Heilberg IP: Caffeine intake by patients with autosomal dominant polycystic kidney disease. Braz J Med Biol Res 45: 834-840, 2012
98. Orth SR, Stöckmann A, Conradt C, Ritz E, Ferro M, Kreusser W, Piccoli G, Rambausek M, Roccatello D, Schäfer K, Sieberth HG, Wanner C, Watschinger B, Zucchelli P: Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 54: 926-931, 1998
99. Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003
100. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004
101. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP: Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006
102. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008
103. Grantham JJ: Therapy for polycystic kidney disease? It ' s water, stupid! J Am Soc Nephrol 19: 1-7, 2008
104. Torres VE, Bankir L, Grantham JJ: A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 4: 1140-1150, 2009
105. Bankir L, Bouby N, Ritz E: Vasopressin: A novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 9: 223-239, 2013
106. Wang CJ, Grantham JJ, Wetmore JB: The medicinal use of water in renal disease. Kidney Int 84: 45-53, 2013
107. Wang CJ, Creed C, Winklhofer FT, Grantham JJ: Water prescription in autosomal dominant polycystic kidney disease: Apilot study. Clin JAm Soc Nephrol 6: 192-197, 2011
108. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT: Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 11: 1033-1037, 1990
109. Sherstha R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, Everson GT: Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 26: 1282-1286, 1997 Editorial assistance was provided by Catherine Fontana, Geoff Marx, and Barry M. Weichman of BioScience Communications (New York, NY), which was funded by Otsuka America Pharmaceutical, Inc.